Krane Funds Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-4,682
Closed -$519K 141
2025
Q2
$519K Buy
4,682
+498
+12% +$53K 0.02% 54
2025
Q1
$469K Sell
4,184
-1,348
-24% -$139K 0.01% 56
2024
Q4
$511K Sell
5,532
-575
-9% -$51.8K 0.02% 42
2024
Q3
$512K Buy
6,107
+182
+3% +$13.9K 0.02% 50
2024
Q2
$407K Sell
5,925
-114
-2% -$7.61K 0.02% 64
2024
Q1
$436K Buy
6,039
+510
+9% +$39.2K 0.02% 76
2023
Q4
$448K Buy
+5,529
New +$430K 0.02% 76
2023
Q3
Sell
-4,047
Closed -$312K 110
2023
Q2
$312K Buy
4,047
+107
+3% +$8.53K 0.02% 87
2023
Q1
$325K Sell
3,940
-2,682
-41% -$222K 0.01% 81
2022
Q4
$568K Sell
6,622
-835
-11% -$66.1K 0.02% 54
2022
Q3
$460K Sell
7,457
-172
-2% -$10.8K 0.02% 75
2022
Q2
$472K Sell
7,629
-1,020
-12% -$63.2K 0.02% 83
2022
Q1
$514K Buy
8,649
+1,302
+18% +$83.2K 0.02% 145
2021
Q4
$533K Sell
7,347
-386
-5% -$26.6K 0.01% 142
2021
Q3
$540K Sell
7,733
-759
-9% -$53.3K 0.01% 143
2021
Q2
$585K Buy
8,492
+2,125
+33% +$142K 0.02% 141
2021
Q1
$411K Buy
6,367
+1,951
+44% +$126K 0.02% 249
2020
Q4
$257K Buy
+4,416
New +$266K 0.01% 246

Other funds holding GILD

Krane Funds Advisors's GILD Position: Q3 2025 in Review

Krane Funds Advisors sold out of Gilead Sciences (GILD) in Q3 2025, closing a stake of 4,682 shares — an estimated $519K sold.

Krane Funds Advisors first reported a position in GILD in Q4 2020 and held it in 18 quarters. The position peaked at $585K in Q2 2021. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.

  • Krane Funds Advisors reported no remaining Gilead Sciences position as of Q3 2025 after selling out during the quarter.
  • Krane Funds Advisors sold 4,682 Gilead Sciences shares in Q3 2025, an estimated $519K.
  • Krane Funds Advisors first reported a position in Gilead Sciences in Q4 2020 and held it in 18 quarters.
  • Krane Funds Advisors's Gilead Sciences position peaked at $585K in Q2 2021.
  • 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.

Based on Krane Funds Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.